BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 8, 2005
View Archived Issues
Pivotal Phenserine Data Drop Axonyx's Stock By 62 Percent
Axonyx Inc. lost almost two-thirds of its value on Monday with news that its lead Alzheimer's disease product, Phenserine, failed in a European Phase III trial. (BioWorld Today)
Read More
Specialty Pharma Partnering Can Bring Focus, Expertise
Read More
Takeda Paying $270M Cash For Syrrx Presence In States
Read More
Intarcia IPO Seeks $86.25M For Cancer, HCV Therapies
Read More
Vicuron Reports Positive Phase III Results, Plans Third-Quarter NDA
Read More
Other News To Note
Read More
Appointments And Advancements
Read More